The problem the researchers set out to solve is one of the most stubborn technical bottlenecks in cell biology. Antibodies are superb molecular recognition machines, capable of distinguishing protein conformations, aggregation states, and individual post-translational modifications with extraordinary precision. But the plasma membrane is an impenetrable barrier to these Y-shaped proteins. Traditional workarounds each carry significant drawbacks. Microinjection and electroporation can introduce antibodies into cells but are slow, laborious, and damaging, making them poorly suited for treating large populations. Genetically encoded intrabodies can be expressed inside cells, but they demand viral vectors or transfection, require days to weeks of expression, and typically perturb all forms of a target protein at once rather than a single modified species. In many cases, antibodies that do get taken up remain trapped in endosomes, never reaching their cytoplasmic targets.

The Northwestern team, led by Kirsten Viola, Brett Chromy, Mary Lambert, and William Klein of the Department of Neurobiology, turned to a cationic lipid with an unusual pedigree. The molecule, 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine, abbreviated DOPC+, was originally developed as a gentle vehicle for DNA transfection. The CLD procedure is remarkably simple and takes less than an hour from start to finish. First, the lipid is dried into a thin film inside a glass tube under a stream of nitrogen or argon. Next, a small volume of antibody solution is added to resuspend the film, and the mixture is vortexed into a milky suspension of multi-lamellar vesicles. A brief sonication step breaks these large vesicles down into small unilamellar liposomes roughly 50 nanometers in diameter, as confirmed by atomic force microscopy. Finally, the antibody-lipid complexes are diluted into serum-free culture medium and applied to the cells, where delivery occurs in under thirty minutes.

To validate the platform, the researchers first tested whether CLD could ferry small molecules across the membrane. Fluorescent BODIPY-phallacidin, a probe that binds actin filaments, was delivered into cultured 3T3 fibroblasts and B103 rat neuroblastoma cells, where it lit up stress fibers and actin bundles at the tips of filopodia within twenty minutes. A synthetic peptide derived from the N-terminal domain of the tyrosine kinase Fyn was likewise delivered into B103 cells and dispersed homogeneously through the cytoplasm. Dextrans ranging from 10 to 70 kilodaltons also crossed successfully. The critical control came from mixing unencapsulated antibody with empty liposomes: essentially no intracellular labeling resulted. The antibody must be incorporated into the lipid complex itself; simply bathing cells in antibody alongside empty vesicles accomplishes nothing.

The decisive experiments involved full-length antibodies. When N1E-115 mouse neuroblastoma cells were incubated with liposomes loaded with Fyn3 antibody, the resulting staining pattern across the population was nearly identical to that obtained by conventional immunocytochemistry of fixed, permeabilized cells. Antibodies against vinculin and paxillin—two components of focal adhesions, the protein complexes that anchor cells to their substrate—were delivered into B103 cells and correctly localized to discrete puncta at the tips of growth cones, exactly where these proteins are known to reside. Because focal contacts have such a characteristic, spatially restricted distribution, they served as a rigorous test of whether delivered antibodies retain their targeting function in the living cytoplasm. They did, without exception.

With the delivery system validated, the team deployed their Alzheimer’s-relevant cargo. PHF-1 is a monoclonal antibody raised against paired helical filament tau, the hyperphosphorylated species that accumulates in the neurofibrillary tangles that define Alzheimer’s disease progression. It binds tau phosphorylated at serines 396 and 404, epitopes widely used as pathological biomarkers in tissue staining and in emerging fluid diagnostics. Yet the same epitope is not exclusively pathological. Earlier work had shown that PHF-1-reactive tau appears transiently in the developing nervous system—both in human fetal brain and in embryonic chick retina—where tau phosphorylation is dynamically regulated during axon formation. The B103 and N1E-115 cell lines used in the study constitutively express the PHF-1 epitope, making them convenient models.

When encapsulated PHF-1 was delivered into B103 cells, it produced filamentous staining patterns identical to those seen with traditional fixation-and-permeabilization labeling, confirming that the antibody had escaped the endosomal route and accessed its cytoskeletal target. Delivery into primary chick retinal neurons—an important demonstration, since these post-mitotic cells cannot be expanded and are far more fragile than immortalized lines—was similarly efficient, with virtually every neuron in the culture taking up the antibody. Crucially, cells tolerated the procedure well: cultures incubated with the complexes for more than twenty-four hours showed no detectable toxicity, and up to 100 micrograms of DOPC+ per milliliter of medium was tolerated by rat hippocampal neurons, chick retinal neurons, and the B103 line alike.

The surprise came when the researchers monitored living B103 cultures by time-lapse imaging after PHF-1 delivery. Within approximately three hours, cells receiving active PHF-1 exhibited dramatic neurite retraction and cell-body rounding—their slender processes withdrew, and the neurons collapsed into rounded shapes. Cultures receiving heat-inactivated PHF-1, empty vehicle liposomes, or other intracellular antibodies showed no such response. This specificity rules out a nonspecific consequence of liposomal delivery or of antibody accumulation inside cells. Instead, it points to a direct functional consequence of antibody binding: engaging the PHF-1-reactive tau pool apparently disrupts processes that maintain neuronal architecture. The authors are careful about interpretation. They note that the mechanism remains unknown—binding might interfere with physiological interactions between phosphorylated tau and the cytoskeleton, alter tau’s conformation, trafficking, or subcellular organization, or, because antibodies are multivalent, crosslink tau species in ways that perturb their function. Nor do the data imply that phosphorylation at Ser396/404 is itself uniquely required for neurite maintenance; the phenotype implicates the PHF-1-reactive population as a whole.

What the finding does suggest is provocative: a tau phospho-form celebrated as a hallmark of neurodegeneration may also perform a physiological job in healthy or developing neurons, one that becomes dysregulated in disease. This dual identity fits a broader theme in modern proteomics. Proteoforms—distinct versions of a protein generated by post-translational modifications such as phosphorylation, acetylation, truncation, or ubiquitination—can carry opposite biological activities, and recent mass-spectrometry efforts have mapped increasingly detailed tau proteoform landscapes in human brain. But defining what each proteoform actually does in a living cell has lagged far behind cataloguing what it is. Genetic approaches perturb the entire protein, not a single modified species.

CLD offers a way to close that gap. Because it delivers pre-formed, full-length antibodies acutely and broadly across a culture, it converts antibodies from passive imaging reagents into active perturbation tools, allowing researchers to interrogate specific endogenous proteoforms in their native cellular context within hours rather than weeks. In the present study, PHF-1 was initially little more than model cargo; its introduction revealed a robust and previously unappreciated phenotype. The same strategy could now be applied to disease-associated species across a range of neurodegenerative disorders. The authors caution that key questions remain—whether the neurite retraction is reversible, what downstream cytoskeletal changes mediate it, and whether the same response occurs in intact neural circuits in vivo. But the demonstration that a simple cationic lipid can deliver functional antibodies safely into populations of living neurons, and that doing so can expose an unexpected function of an Alzheimer’s-linked tau species, marks CLD as a versatile new window onto the hidden workings of the neuronal interior.

Subject of Research: Cationic liposomal delivery of functional antibodies into living neurons and the role of phosphorylated tau in neurite integrity

Article Title: Safe and efficient intracellular delivery of functional antibodies into cultured neural cells shows a role for Alzheimer’s-relevant tau phosphorylation in cell integrity

Article References: Viola, K. L., Chromy, B. A., Nowar, R., Lambert, M. P., & Klein, W. L. (2026). Safe and efficient intracellular delivery of functional antibodies into cultured neural cells shows a role for Alzheimer’s-relevant tau phosphorylation in cell integrity. Frontiers in Dementia, 5, Article 1737082. https://doi.org/10.3389/frdem.2026.1737082

Image Credits: AI Generated

DOI: 10.3389/frdem.2026.1737082

Keywords: cationic liposomes, intracellular antibody delivery, tau phosphorylation, PHF-1, Alzheimer's disease, neurons, neurite retraction, proteoforms, neurodegeneration, DOPC+, cytoskeleton, primary neuronal cultures

Proteins are not static entities. After they are translated from messenger RNA, they undergo a dizzying array of chemical modifications: phosphate groups are added and removed, the protein backbone is clipped by proteases, small protein tags such as ubiquitin are attached, and amino acids can be chemically altered in dozens of other ways. Each unique combination of modifications and sequence variants constitutes a distinct proteoform. The trouble is that two proteoforms of the same protein can behave in radically different ways inside a cell, one folding into a harmless shape and another seeding the toxic aggregates that kill neurons. Standard proteomics methods, which typically chop proteins into small peptides before identifying them, lose the connectivity information that reveals which modifications coexisted on the same original molecule. As a result, the proteoform landscape of even a well-studied protein like tau has remained only partially charted.

Iterative Mapping of proteoforms tackles this problem by interrogating individual protein molecules directly, preserving the integrity of each proteoform throughout the measurement. The core idea is to perform repeated cycles of imaging-based readout on single immobilized molecules, building up a pattern of signals that serves as a molecular fingerprint. Because each molecule is observed on its own, the resulting data reflect genuine single-molecule heterogeneity rather than population averages. This matters enormously for tau, where rare proteoforms may be the biologically decisive species. A modification present on only one percent of tau molecules could be invisible to bulk measurements, yet a small pool of aberrantly modified molecules might be sufficient to nucleate the pathological aggregates that spread through the brain in Alzheimer’s disease.

The scale of the new approach is what sets it apart. Earlier single-molecule protein characterization methods, while conceptually elegant, were limited in throughput, making it impractical to survey the full diversity of proteoforms in complex biological samples. Iterative Mapping achieves large-scale measurement by combining highly parallel detection with an iterative readout strategy, allowing millions of individual molecules to be characterized in a single experiment. The researchers validated the technique using control samples of known composition, a critical step that established the method’s accuracy in quantifying predefined proteoform groups. Only after demonstrating that the technique could correctly identify and count proteoforms in mixtures of known makeup did the team apply it to more complex and clinically relevant material.

Tau is an unusually challenging target for such an analysis. In the human brain, the MAPT gene produces six major isoforms of tau through alternative splicing, differing in the number of microtubule-binding repeats and N-terminal inserts. On top of this isoform diversity, tau carries an enormous number of possible phosphorylation sites, with dozens of serine, threonine, and tyrosine residues that can be modified individually or in combination. The phosphorylation state of tau governs its normal function in stabilizing microtubules, the structural scaffolds of neurons, but hyperphosphorylation promotes tau’s detachment from microtubules, its misfolding, and ultimately its aggregation into the paired helical filaments that compose neurofibrillary tangles. Because the biological consequences of phosphorylation depend on which sites are modified together on the same molecule, knowing the total amount of tau phosphorylation in a sample is far less informative than knowing the actual distribution of proteoforms.

The demonstration in model systems used in tauopathy research provides a bridge between controlled validation experiments and human tissue. Cell and animal models of tauopathy are workhorses of the field, used to test hypotheses about how tau becomes pathological and to screen candidate therapies. Applying Iterative Mapping to these systems allows researchers to characterize how the tau proteoform landscape shifts as disease-like states develop, and to compare the proteoform signatures of different models against one another. Such comparisons could help resolve a persistent problem in the field: different model systems recapitulate different aspects of tau pathology, and it has been difficult to know which models most faithfully reflect the human disease. A quantitative, single-molecule proteoform census offers a new common currency for making those comparisons.

The most striking application, however, is the analysis of human-derived brain tissue samples. Post-mortem brain tissue from individuals with Alzheimer’s disease and related tauopathies is a precious and technically difficult resource, often available in limited quantities and frequently affected by post-mortem delays and variable tissue quality. Demonstrating that Iterative Mapping can extract meaningful proteoform quantification from such material establishes the method’s readiness for real-world translational research. The ability to profile tau proteoform groups directly in human brain tissue means that hypotheses generated in models can now be tested against the actual molecular substrate of disease, and that proteoform patterns associated with specific diagnoses, disease stages, or clinical outcomes can be systematically searched for.

The implications for drug development could be substantial. A growing number of therapeutic strategies target tau directly, including antisense oligonucleotides designed to reduce tau production, immunotherapies intended to clear pathological tau species, and small molecules aimed at inhibiting the kinases that phosphorylate tau. Each of these approaches would benefit from a measurement technology that can report precisely which proteoforms are reduced or altered following treatment. Bulk phosphorylation assays can indicate that total tau phosphorylation has decreased, but they cannot reveal whether the specific proteoform groups thought to drive toxicity have been affected. Single-molecule proteoform quantification provides exactly that granularity, potentially enabling biomarker-guided clinical trials in which molecular responses are monitored at the level of individual protein species.

Beyond tau, the demonstration establishes a general template for large-scale single-molecule proteoform analysis that could be extended to other proteins of biomedical importance. Alpha-synuclein in Parkinson’s disease, huntingtin in Huntington’s disease, TDP-43 in amyotrophic lateral sclerosis, and amyloid precursor protein in Alzheimer’s disease all share the same basic challenge: their pathological behavior depends on proteoform-level details that bulk methods obscure. If Iterative Mapping can be adapted to these targets, the technology could catalyze a broader shift in proteomics toward intact-protein, single-molecule measurement, complementing the peptide-centric workflows that have dominated the field for decades. The convergence of single-molecule imaging, iterative biochemical readout, and computational analysis reflected in this work suggests that the long-sought goal of routinely reading complete proteoforms is moving from aspiration toward practice.

Challenges remain before such methods become routine in laboratories and clinics. Sample preparation for single-molecule analysis must preserve labile modifications, the computational pipelines for interpreting iterative readout patterns must be robust across diverse sample types, and the proteoform groups quantified today represent a subset of the full molecular diversity that likely exists in brain tissue. Nevertheless, the demonstration that large-scale, single-molecule proteoform measurement is achievable, validated against known controls, and applicable to human tissue marks a genuine advance. For a protein like tau, whose transformation from a neuronal workhorse into a killer aggregate has puzzled researchers for decades, the ability to count and classify its molecular forms one molecule at a time may finally provide the resolution needed to understand, and ultimately interrupt, the progression of tauopathy.

Subject of Research: Large-scale single-molecule measurement of intact tau proteoforms using Iterative Mapping

Article Title: Large-scale single-molecule analysis of tau proteoforms

Article References: Joly, J., Budamagunta, V., Zhang, Z., Nortman, B., Jouzi, M., Bhatnagar, R., Egertson, J. D., Flaster, M. E., Grothe, R., Guha, S., Kaneshige, K., McVey, K., Nelson, N., Perera, R. T., Tan, S. J., Trinh, T., Arnott, D., Lipka, J., Pandya, N. J., … Mallick, P. (2026). Large-scale single-molecule analysis of tau proteoforms. Nature Methods, 23(9), 1786-1797. https://doi.org/10.1038/s41592-026-03188-6

Image Credits: AI Generated

DOI: 10.1038/s41592-026-03188-6

Keywords: tau, proteoforms, single-molecule analysis, Iterative Mapping, tauopathy, Alzheimer's disease, phosphorylation, proteomics, neurodegeneration, brain tissue, biomarkers, drug development